RARRES2 and myeloid sarcoma: In CSF, chemerin levels did not differ between controls (mean: 31.06 ± 8.25 ng/mL) and neurological patients, whereas patients with either MS (mean: 27.80 ± 8.69 ng/mL) (vs. CVD: p = 0.001; vs. epilepsy: p = 0.010) or infectious diseases (mean: 26.74 ± 10.67 ng/mL) (vs. CVD: p = 0.005; vs. epilepsy: p = 0.025) exhibited lower CSF chemerin levels when compared to patients suffering from CVD (mean: 35.06 ± 10.87 ng/mL) or epilepsy (mean: 34.77 ± 12.48 ng/mL) (Figure 4B).